MedWatch

Set-in-stone criteria will reduce risk for new biotech fund

Several boxes must be ticked off before new Danish-Swedish biotech fund Sound Bioventures is ready to invest. A high-energy team, the right development stage and an indication on the smaller side are all on the list, but medtech and diagnostic firms have been excluded, says founding partner Casper Breum.

Casper Breum, founding partner at Sound Bioventures | Photo: Casper Breum, Privatfoto

For many years, promising Danish life science firms and imaginative biotech entrepreneurs only had a few funds to turn to when raising capital to secure their futures: Lundbeckfonden, the Novo Nordisk Foundation and Sunstone Life Science Ventures.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs